Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Barchart · 3d ago

                             Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.